A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy.

Trial Profile

A Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Oral Suberoylanilide Hydroxamic Acid (Vorinostat, MK-0683) in Patients With Advanced Malignant Pleural Mesothelioma Previously Treated With Systemic Chemotherapy.

Completed
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Vorinostat (Primary)
  • Indications Mesothelioma
  • Focus Adverse reactions; Biomarker; Registrational; Therapeutic Use
  • Acronyms VANTAGE 014; VANTAGE-14
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 11 Aug 2017 This trial has been Discontinued in Belgium.
    • 03 Apr 2012 Actual patient number changed from 661 to 662 as reported by ClinicalTrials.gov.
    • 03 Apr 2012 Actual patient number changed from 661 to 662 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top